Is AURINIA PHARMACEUTICALS Stock a good buy in 2022, according to Wall Street analysts? The consensus among 4 Wall Street analysts covering (NASDAQ: AUPH) stock is to Buy AUPH stock.
Similarly Will AUPH stock go up? Stock Price Forecast
The 8 analysts offering 12-month price forecasts for Aurinia Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 34.00 and a low estimate of 18.00. The median estimate represents a +136.09% increase from the last price of 11.86.
Is Aurinia Pharmaceuticals a good stock to buy? Aurinia Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Additionally, Why is Aurinia Pharmaceuticals a buy?
Investors and analysts rating Aurinia Pharmaceuticals a Buy are doing so based on its late-stage positioning in LN treatment. The FDA’s NDA fast-track approval shortens the research window to under 12 months, which means we’ll know by the end of 2021 whether the treatment works.
Where is Aurinia pharmaceuticals?
Company Overview
Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs. The Company’s head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland.
Why is Aurinia stock dropping? Despite beating Street forecasts with its Q4 2021 financials, Aurinia Pharmaceuticals (NASDAQ:AUPH) has lost ~20% in the pre-market Monday after the commercial-stage biopharmaceutical company disappointed investors with its sales outlook for 2022.
How many employees does Aurinia? Compare AUPH With Other Stocks
| Aurinia Pharmaceuticals Inc Annual Number of Employees | |
|---|---|
| 2020 | 294 |
| 2019 | 62 |
| 2018 | 39 |
| 2017 | 33 |
Why is AUPH stock going down? Why Aurinia Pharmaceuticals Tumbled Despite Its ‘Aggressive’ 2022 Outlook. Aurinia topped fourth-quarter expectations Monday, but AUPH stock plummeted on lackluster guidance for lupus treatment Lupkynis.
Why is OCGN stock down?
Ocugen’s OCGN stock declined 3.8% on Tuesday after the FDA placed a clinical hold on a phase II/III immuno-bridging and broadening clinical study on its COVID-19 vaccine, Covaxin.
Will OCGN go up? Long-term Ocugen stock forecast 2022-2025
Algorithm-based forecasting service Wallet Investor gave a positive OCGN stock price forecast. The site predicted that the share price could climb over the next year, to $7.2 by March 2023.
Is OCGN a buy or sell?
Ocugen has received a consensus rating of Hold. The company’s average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Is OCGN a good stock to buy? Is OCUGEN Stock a good buy in 2022, according to Wall Street analysts? The consensus among 3 Wall Street analysts covering (NASDAQ: OCGN) stock is to Hold OCGN stock.
Why did OCGN stock go up?
Shares of Ocugen ( OCGN 0.00% ) had skyrocketed by 19.1% as of 11:15 a.m. ET on Tuesday. The huge gain came after the company announced that the Food and Drug Administration (FDA) had lifted the clinical hold on its investigational new drug (IND) application for COVID-19 vaccine Covaxin.
What is the target price for OCGN stock?
Stock Price Target OCGN
| High | $ 15.00 |
|---|---|
| Median | $ 7.00 |
| Low | $ 4.00 |
| Average | $ 8.25 |
| Current Price | $ 2.76 |
What is the prediction for OCGN stock? Stock Price Forecast
The 4 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a +153.62% increase from the last price of 2.76.
Who owns OCGN? Top 10 Owners of Ocugen Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.21% | 11,209,731 |
| The Vanguard Group, Inc. | 4.69% | 10,096,039 |
| Geode Capital Management LLC | 1.52% | 3,274,335 |
| JPMorgan Asset Management (UK) Lt… | 1.49% | 3,197,615 |
Is Ocugen a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank.
…
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.93% |
| 2 | Buy | 18.44% |
| 3 | Hold | 9.99% |
| 4 | Sell | 5.61% |
What kind of stock is OCGN? Key Data
| Label | Value |
|---|---|
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| 1 Year Target | $7.00 |
| Today’s High/Low | $3.02/$2.75 |
Is Ocugen vaccine approved?
Ocugen and Bharat Biotech have been partners since 2020 to develop the vaccine, which has been authorized in India for people ages 12 and up.
Why is Ocugen stock up today? What happened. Shares of Ocugen ( OCGN -7.07% ) had skyrocketed by 19.1% as of 11:15 a.m. ET on Tuesday. The huge gain came after the company announced that the Food and Drug Administration (FDA) had lifted the clinical hold on its investigational new drug (IND) application for COVID-19 vaccine Covaxin.
What is Nio price target?
The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 32.97, with a high estimate of 86.67 and a low estimate of 24.11. The median estimate represents a +74.65% increase from the last price of 18.88.
Is Vanguard invested in OCGN? 2022-02-10 – Vanguard Group Inc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 10,605,494 shares of Ocugen Inc (US:OCGN). This represents 5.32 percent ownership of the company.
How many shares are there of OCGN? Share Statistics
| Avg Vol (3 month) 3 | 12.01M |
|---|---|
| Shares Outstanding 5 | 215.37M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 195.66M |
| % Held by Insiders 1 | 2.55% |
Who owns the most shares of OCGN?
Largest shareholders include State Street Corp, BlackRock Inc., Vanguard Group Inc, XBI – SPDR(R) S&P(R) Biotech ETF, VTSMX – Vanguard Total Stock Market Index Fund Investor Shares, IWM – iShares Russell 2000 ETF, Jpmorgan Chase & Co, Geode Capital Management, Llc, VEXMX – Vanguard Extended Market Index Fund Investor …
